Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Income towards Parent Company: 2016-2024

Historic Income towards Parent Company for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to -$43.3 million.

  • Mereo BioPharma Group's Income towards Parent Company rose 53.18% to -$7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.6 million, marking a year-over-year increase of 8.26%. This contributed to the annual value of -$43.3 million for FY2024, which is 46.79% down from last year.
  • Mereo BioPharma Group's Income towards Parent Company amounted to -$43.3 million in FY2024, which was down 46.79% from -$29.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Income towards Parent Company ranged from a high of $17.2 million in FY2021 and a low of -$210.1 million during FY2020.
  • In the last 3 years, Mereo BioPharma Group's Income towards Parent Company had a median value of -$42.2 million in 2022 and averaged -$38.3 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Income towards Parent Company slumped by 372.29% in 2020, and later spiked by 108.16% in 2021.
  • Mereo BioPharma Group's Income towards Parent Company (Yearly) stood at -$210.1 million in 2020, then soared by 108.16% to $17.2 million in 2021, then slumped by 346.13% to -$42.2 million in 2022, then skyrocketed by 30.21% to -$29.5 million in 2023, then plummeted by 46.79% to -$43.3 million in 2024.